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ABSTRACT 
Acute Myeloid Leukemia (AML) is a cancerous disease that is defined by the 
inability to produce functional and mature blood cells, as well as the uncontrolled 
proliferation due to failure to undergo apoptosis of abnormal cells.  The most common 
therapy for Leukemia, chemotherapy, has proven only to be partially efficient since it 
does not target the leukemic stem cells (LSCs) that have a high self-renewal and 
repopulation capacity and result in remission of the disease.  Therefore targeting 
LSCs will provide more efficient therapy.  One way to achieve this would be to 
inhibit their homing capability to the bone marrow.  It has recently been shown that 
CD44, an adhesive molecule, plays a crucial role in cell trafficking and lodgement of 
both normal and leukemic stem cells.  More importantly anti-CD44 monoclonal 
antibodies, along with its ability to induce differentiation of leukemic blasts, it inhibits 
specifically the homing capacity of LSCs to their micro-environmental niches.  
However, these molecular mechanisms that underlie the inhibition of homing have yet 
to be determined.  To address these questions we conducted in vitro adhesion and 
blot-rolling assays to analyze the adherence and rolling capacity of these LSCs before 
and after treatment with anti-CD44 monoclonal antibody (mAb).  Since 
glycosyltransferases play a crucial role in post translational carbohydrate decoration 
on adhesion molecules, we analyzed the expression (using quantitative PCR) of the 
different glycosyltransferases expressed in LSC's before and after CD44 ligation 
(mAb treatment).  Furthermore, we analyzed differentiation by flow cytometric 
analysis of treated and non-treated LSC's.  We anticipate that our results will set forth 
new insights into targeted therapies for AML.            
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I. Introduction and Literature Review 
1.1 Acute Myeloid Leukemia 
Acute myeloid leukemia (AML) is a heterogeneous clonal disorder of hematopoietic 
progenitor cells that is characterized by a blockage of differentiation and an 
accumulation of immature non-functional myeloid cells in the blood (see Figure 1).  It 
is the most common malignant myeloid disorder among adults and the incidence 
increases with age
1
. AML is most commonly caused by genetic mutation; (e.g., 
translocation between chromosomes 15:17, responsible for retinoic acid receptor 
alpha RARA and PML genetic fusion in the case of AML3, or the 8:21 translocation) 
(1-3).  
 
Figure 1: Development of Leukemia.  Mutations of the normal hematopoietic 
stem/progenitor cell leads to the formation of the leukemic stem cell.  This leukemic 
stem cell differentiates down a path and is blocked at different stages leading to the 
accumulation of immature blasts in bone marrow and blood vessels(4). 
 
According to the French-American-British (FAB) classification, AML can be divided 
into the following subclasses based on the differentiation of the malignant cells: 
                                                        
1 (date downloaded 10 July 2011: 
http://www.lls.org/#/diseaseinformation/leukemia/acutemyeloidleukemia/incidence/) 
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AML-M0 and -M1 show minimal differentiation; AML-M2 includes a minor 
maturing granulocytic component, whereas AML-M3 (APL) has a dominating 
accumulation of promyelocytes; AML-M4 and -M5 show myelomonocytic 
differentiation; AML-M6 has an erythroid predominance; and AML-M7 is the acute 
megakaryoblastic leukemia (5, 6).  AML treatment, consisting of intensive 
chemotherapy alone or in combination with stem cell transplantation when possible, is 
associated with a relatively high risk of relapse and a long-term survival < 50% (7).  
 
The introduction of differentiating therapy with the all-trans retinoic acid (ATRA) has 
drastically improved the treatment of type 3 AML (APL) (8).  Therefore, current 
efforts in clinical research focus on the assessment of targeted therapies to find 
differentiating agents that may be applicable to all types of AML.  
It has been shown that specific monoclonal antibodies (mAbs, H90 and A3D8) 
directed to CD44, a cell surface antigen that is strongly expressed on human AML 
blasts, is capable of triggering terminal differentiation of leukemic blasts in AML1 to 
AML5 subtypes. These results have raised the prospect of developing a CD44-
targeted differentiation therapy in all AML types. Anti-CD44 triggering has also been 
shown to induce the differentiation of AML cell lines, inhibit their proliferation and, 
in some cases, induce their apoptosis.  However, completely and permanently curing 
AML will require the elimination of the leukemic stem cells (LSCs), the only cell 
type that is capable of initiating and maintaining the disease. 
 
Mice were used to model the leukemic disease by transplanting the mouse with 
human AML cells.  The disease can be transmitted by transplanting bone marrow 
cells from one leukemic mouse to another serially for many generations.  The 
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capability to transfer this cancer is caused by the presence of cancer stem cells (LSCs) 
within the bone marrow.  A study by Jin et al (9) reported that introducing an 
activating CD44 mAb into leukemic mice, significantly reduced the leukemic 
repopulation capability in serially transplanted animals suggesting that this antibody is 
targeting LSCs in particular. 
These studies suggest that CD44 might be a key regulator of AML LSCs. However, 
the molecular mechanisms underlying eradication of quiescent AML LSCs have yet 
to be determined. 
 
The glycoprotein CD44 is an adhesion molecule expressed on all types of stem cells 
in the body but also plays a crucial role in the homing of normal hematopoietic stem 
cells and leukemic stem cells (10-13). Thus this molecule has become the number one 
target for the treatment and study of molecular mechanisms underlying homing (14).  
 
1.2 Multistep Paradigm of Homing 
The process of homing of a cell to a tissue, in this case the HSCs or the LSCs to bone 
marrow, is a multistep process that depends on the interaction of molecules expressed 
on the surface of the migrating cell interacting with counter-molecules on the surface 
of the endothelial cells that line the blood vessels within a specific tissue.  It is 
composed of 4 major steps and each step in the process is a pre-requisite for the 
subsequent one.  There are a number of different molecules that are important in this 
process and that mediate each of these steps (see Figure 2).  The first step in this 
process or STEP 1 is tethering and rolling, which is mediated by selectins, a family of 
carbohydrate binding proteins, expressed on the endothelial cells and their interaction 
with the selectin ligands expressed on the surface of the migrating cell.  STEP 2, 
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Integrin activation, is controlled by the binding of chemokine receptors on the surface 
of the migrating cell to the corresponding chemokines expressed on the endothelial 
cells.  STEP 3, cell arrest is mediated by the binding of the activated integrin, on the 
surface of the migrating cell, to its counter-receptor (eg. ICAM/ VCAM) on the 
surface of the endothelial cells.  Once the cell stops it will be able to make its way 
through the junctions between the endothelial cells and transmigrate (STEP 4) 
through the endothelium and into the tissue (i.e. the bone marrow) in order to find its 
appropriate niche (7, 9, 10, 15-23).   
 
Although each step in this process is important, the interactions mediating the first 
step of this cascade are absolutely required for initiating the process.  As a result, 
studying the selectins and their ligands becomes a key to regulate the migration 
process of cells to specific organs. 
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Figure 2: Multistep paradigm of stem cell homing to the bone marrow. The process 
begins with the tethering and rolling of the stem cell on the endothelium of the blood 
vessel and is followed by integrin activation, firm adhesion and transmigration 
through endothelial cells into the tissue (i.e. the bone marrow)(10).  
 
The selectins are a family of adhesion molecules that are comprised of three family 
members, L-selectin, P-selectin and E-selectin  (Figure 3).  L-selectin (CD62L) is 
expressed on leukocytes and is most important in mediating the homing of naïve T 
cells to the lymph nodes as a mean to survey the body for infection in the adaptive 
immune response.  P-selectin (CD62P) was first found to be expressed on platelets.  
Later P-selectin was found to have a critical role in mediating the migration of 
activated immune cells to inflammatory sites during the adaptive immune response.  It 
has also been associated with the homing of T cell progenitor cells from the bone 
marrow to the thymus due to its constitutive expression on the thymic endothelium 
(19, 24).  E-selectin (CD62E) is expressed on endothelial cells and, like P-selectin, is 
also stimulated to become expressed on the endothelium around inflammatory sites 
and is important in the recruitment of immune cells to these sites (25).  E-selectin has 
also been shown to be crucial to the homing of hematopoietic stem cells to the bone 
marrow due to its constitutive expression in the bone marrow endothelial cells (18, 
26-28). 
11 
 
 
Figure 3: The family of selectins, L-selectin, P-selectin, and E-selectin.  The three 
selectins share many of the same domains namely a lectin binding domain, an EGF-
like domain, a number of (according to the picture complement regulatory repeats) 
complementary regulatory repeat, a transmembrane domain, and a cytoplasmic 
domain.  The lectin binding domain is most important in mediating the interaction 
between the selectin and its ligand (25).  
 
The binding of selectins to their corresponding ligands is mediated through the 
interaction of the lectin binding domain of the selectin to a specific carbohydrate 
decoration, sLe
x
, on the selectin ligand.  In the case of an HSC homing to the bone 
marrow, the lectin binding domain of E-selectin recognizes the sLe
x
 epitope expressed 
on the glycoprotein and/or glycolipid expressed on the stem cell (Figure 4) (17, 18, 
26, 29).   
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Figure 4: The crystal structure illustrating the key interaction between the lectin 
binding domain of E-selectin to sLe
x
 expressed on the E-selectin ligand.  Note that the 
lectin binding domain makes extensive interactions with the fucose (Fuc), galactose 
(Gal) and the sialic acid (NeuNAc) whereas no interactions with the N-
acetylglucosamine (GlcNAc).  This interaction is also divalent cation dependent as 
shown in this structure by the presence of the coordinating Ca
2+
 ion (yellow ball) 
(10). 
 
The formation of this specific sLe
x
 tetrasaccharide (4 carbohydrates) structure occurs 
as a post-translational modification, known as glycosylation, on native proteins (and 
lipids) catalyzed by glycosyltransferases expressed within the Golgi apparatus.  There 
are 2 different types of glycosylation that can occur: 1) N-glycosylation occurs on 
Asparagine (Asn) residues of the glycoprotein backbone and 2) O-glycosylation 
occurs on Serine (Ser) and Threonine (Thr) (in a consensus sequence; Asn-any amino 
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acid-Ser/Thr) residues of the glycoprotein backbone.  The glycosyltransferases are 
located throughout the cis, medial and trans Golgi network.  As the glycoprotein 
makes its way through the compartments in the Golgi, if the appropriate consensus of 
amino acids exists, then the sugars will be added in an assembly line fashion 
depending on which glycosyltransferases are expressed in that particular cell.  Each 
glycoysltransferase adds on a very specific sugar to the growing polysaccharide 
(sugar) chain in a very specific orientation.  The addition of four carbohydrates is the 
key to the creation of the sLe
x
 structure.  As illustrated in Figure 5, the sequential 
addition of N-acetylglucosamine (added by N-acetylglucosaminyltransferase) and 
galactose (added by galactosyltransferase) creates a lactosamine.  This lactosamine is 
then capped with the addition of sialic acid (added by a sialyltransferase) and fucose 
(added by a fucosyltransferase) to create the essential sLe
x
 structure.   
 
Figure 5: The addition of glycans to glycoproteins occurs at specific amino acids 
(e.g. Serine (S) and Threonin (T)) via the addition of sugars catalysed by 
glycosyltransferases in the Golgi Apparatus. The repeated lactosamine (N-
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acetylglucosamine [GlcNAc] bound to galactose [Gal]) backbone is capped with 
sialic acid (SA) and fucose (Fuc) catalyzed by sialyltranferases and 
fucosyltransferases respectively.  
 
Many glycoprotein ligands for selectins have been identified.  The most common 
ligand, P-selectin glycoprotein ligand 1(PSGL-1), although first identified as a P-
selectin ligand on white blood cells, was later found to be a ligand for all three 
selectins (30).  In the case of stem cell homing to the bone marrow, E-selectin ligands 
expressed on the migrating HSC have been extensively studied in order to try and to 
improve the efficiency of their homing to the bone marrow during a bone marrow 
transplant (17, 18, 26).  Many E-selectin ligands have been identified such as E-
selectin ligand 1 (ESL-1), PSGL-1 (CLA), HCELL (a specialized glycoform of 
CD44), CD43, as well as sLe
x
 bearing glycolipids.  Although many of these ligands 
have been shown to bind E-selectin, the ligand that have been shown to be most 
important for homing of human HSCs to bone marrow is HCELL (17, 18, 26, 31).  
 
Directed treatment of cancer initiating cells was first identified and applied to 
Leukemia.  Previous study of leukemia has been based on the investigation of the 
microenvironment of the AML cells, the signaling pathways after and before 
treatment, combinations of drugs and antibiotics that would reverse the apoptosis, and 
differentiation blockage of the cells that are highly proliferative (34, 35).  Retinoic 
acid was named as the agent used to fight leukemia and it has had a massive effect in 
reversing the blockage of apoptosis and differentiation in KG1a and HL60 cell lines 
(36, 37).  However, it is known for generating side effects (e.g., toxicity and genetic 
alteration that might result in another type of cancer or inflammation in the body).  
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Recent research in the treatment of Leukemia has explored antibodies targeting 
selectin ligands; H90, A3D8, and J713 all are monoclonal antibodies (mAb) target 
ligation of CD44, with the first two known to activate the function whereas the latter 
is a non function activating antibody (37, 38).  
KG1a and HL60 cell lines are commonly used; both are different stages of Leukemia.  
KG1a represents a minimally differentiated myeloblastic lineage for AML-M0 of the 
disease; whereas HL60 represents AML-M2 and has the capability to mature into 
minor granulocytic cells (32, 33).  
Even though, KG1a cell lines were treated with several antibodies and drugs, they 
refused to differentiate with treatment of antibodies alone.  Therefore recent treatment 
utilizes the combination of A3D8 monoclonal antibody targeted against CD44 and 
Retinoic acid (37, 38).  On the other hand, HL60 was shown to differentiate and go 
under apoptosis after treatment with A3D8 monoclonal antibody alone (37, 38).  
 
Differentiation is usually assessed by morphological analysis, where differentiated 
cells after treatment show a lower nuclear to cytoplasmic ratio and the size of cells 
become bigger (38).  Also fluorescence analysis of different cell markers, like CD15s, 
CD15, CD11b, and CD14 are used to determine the stage of differentiation of each 
cell line after treatment.  For Example, CD15s (sLe
x
) is a marker for a progenitor that 
is comprised of undifferentiated cells.  The cell count of CD15 (Le
x
) increases as cells 
differentiated.  Finally, CD14 is a marker for monocytes and CD11b is a marker for 
Monocyts and granulocytes (39-42).  It has been shown that differentiation markers 
start to appear after 48 hours of treatment and apoptosis increases from day three (37). 
 
1.3 Glycosyltransferases Role in Selectin Ligands formation and HSC Homing  
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Capability 
As previously mentioned, different glycosyltransferases are responsible for 
sialofucosailation or sLe
x
 sugar cap creation on selectin ligands (22, 43-47). After 
creation of the lactosamine backbone of the glycan, core 2 glucosaminyl-
transferases/C2GlcNAcT starts to create core 2 O-glycan branches with its different 
variants.  Variants I and III were shown to be mandatory in the creation of P-selectin 
ligand-1 to be recognized by selectins, and further for rolling capacity (48, 49).  The 
absence of this enzyme will not affect E-selectin interaction with leukocytes (19, 50, 
51).  For ST3GalTs, ST3GalT-IV is the most important because its absence would be 
reflected on a lower rolling capacity at P and E selectin, as well as the creation of 
ESL-1 (52).  On the other hand FT3, FT4, and FT7 are mandatory for the creation of 
ligands to be recognized by E-selectin, and deletions of FT7 have demonstrated lower 
rolling capacity of leukocytes on E- or P- selectin expressing mouse endothelial cells.  
The importance of this is that FT7 acts instead of FT4 when FT4 is dormant (22, 52-
54).  Deficient neutrophils and monocytes in 1,4-GalT-I demonstrate a 20% down-
regulation of P-Selectin Ligands (55).  Furthermore, FT4, FT7, and GalT are 
mandatory enzymes in the creation of sLe
x
 on ESL-1.  It is questionable whether 
treatment of the LSCs with a non-blocking antibody would affect enzymes 
expressions.  Thus further study is necessary concerning the creation of ligands on 
AML cell lines that might influence homing capacity.  
 
Previous literature shows that sialydase, or neuraminidase particularly, responsible for 
the removal of sugar from sialylated markers and thus create a more differentiated 
form of cells.  Additional sialydase has been used successfully in negative controls of 
leukocyte adhesion assay on selectins (22, 42).  Quantitative polymerase chain 
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reactions were positive for presence of sialydase which this study will provide further 
evidence of sialyltransferase expression change.  
 
1.4 Goals and Objectives 
 First Goal: To analyze E-selectin binding to AML cells before and after 
treatment with the function activating mAb targeted against CD44 as a mean 
to induce differentiation of AML cells.  Results from these studies will 
provide insight into the homing abilities of both untreated and treated AML to 
the bone marrow.  We hypothesize that the homing ability of these cells will 
be decreased upon differentiation which can be applied to help eradicate the 
LSC and evade further leukemic disease. 
 
 Second Goal: To quantify the different glycosyltransferases responsible for the 
creation of sLe
x
 epitopes on E-selectin ligands expressed on AML cells before 
and after treatment with the activating CD44 mAb, A3D8.  Specifically to 
determine those glycosyltransferases known play a key role namely 
fucosyltransferases III, IV, VII (FT3, 4, 7), galactosyltransferases, and 
sialyltransferase IV (ST3Gal-IV). 
 
 
 
 
 
II. Materials and Methodologies 
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Cell Lines: KG1a, HL60 and U937 cell lines were purchased from ATCC.  The high 
CLA Clone of KG1a cell line (22D) was developed in our laboratory.  Cells were 
maintained using RPMI-640 (Invitrogen) supplemented with 10% FBS and 1% 
Penicillin /Streptomycin and incubated at 37
o
 C under 5% CO2. 
Antibodies: The anti human CD44 mAb, A3D8 (IgG1) was purchased from Sigma 
Aldrich.  FITC directly conjugated mouse anti human Le
x
 (CD15) mAb (IgM) was 
purchased from Miltenyi Biotech (MACS).  Rat anti human Cutaneous Lymphoid 
Antigen (CLA) (HECA-452, IgM) and secondary Goat anti-Rat IgM antibody PE - 
conjugated were purchased from BD Pharmingen.  E-selectin Ig chimera was 
purchased from R&D Systems.  
Reagents:  May-Grunwald Giemsa Stain was provided from Sigma Aldrich.  Trypan 
Blue was from VWR International.  RNeasy Mini Kit, Trizole R LS 
REAGENT/200ml, 10x Blue Juice, Syber Gold and 1Kb DNA Plus Ladder were 
purchased from Invitrogen.  High Capacity reverse transcription PCR kit is from 
Applied Biosystems and the qPCR Kit was purchased from Roche Applied Science. 
Induction of Differentiation of HL60: HL60 cells were seeded in triplicate at 8x10
5
 
cells /ml, and either treated with 2.5 µg/ ml A3D8 or left untreated and incubated for 
48 hours. 
Cell Proliferation and Viability: Cells were tested for death and proliferation using 
trypan blue dye staining before and after treatment of HL60 cells with A3D8 and cell 
counts were performed using hemocytometer slides. 
Morphology Analysis: was performed to determine the level of differentiation of the 
cells. 
Flow Cytometric Analysis: Expression of surface markers was examined by staining 
in triplicate, 2x10
5
 treated and untreated HL60 cells, with 0.5 μg /ml Antibody in PBS 
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for 20 minutes at 4°C.  To detect differentiation markers, cells were stained for Le
x
 
(CD15) or with Heca-452 (anti-CLA).  Data were analyzed on a FACS Canto flow 
cytometer (BD Biosciences) using FACS Diva software and Flow Jo software. 
Agarose Gel Electrophoresis: RNA extracts were separated by 1% agarose gel 
electrophoresis with 0.5 µg/ml syber gold and were pictured under UV-light 
irradiation.  Figure 6 illustrates the quality of the RNA bands obtained.  
RT-PCR and Primers: Total RNA extraction was performed on 2-6 x 10
6
 cells 
(KG1a, U937, 22D, untreated HL60 and finally A3D8 treated HL60 that were 
harvested after 48 hours of treatment. 
RNA concentrations were analyzed using NanoDrop Spectrophotometer 2000 from 
Thermo Scientific, and initial concentration used described in table (I). 
 
Nucleic Acid Concentration Source of RNA 
347.6 ng/µl KG1a 
398.6 ng/µl CLA High KG1a 
394.7 ng/µl HL60 
817.3 ng/µl Treated HL60 
783.2 ng/µl U937 
Table 1. Initial concentrations of extracted RNA used in RT-PCR and qPCR 
reactions. 
 
Reverse Transcription using 2µg of each RNA extract in 20 µl volume of RT-PCR 
reaction mixture, using Syber-Green Master Mix, provided from Roche applied 
Science, and saved at -80
o
 C.  Efficiency testing for the nineteen pairs of primers were 
performed using the Light Cycler 480 Real-Time PCR system from Roche Applied 
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Science, with serial dilution of the 10µM primers to 1, 2, 4, 8, 16 and 32 folds cDNA 
of KG1a using absolute quantification analysis software.  Amplification curves show 
fluorescence signal and temperature crossing point for each concentration for every 
gene, and standard curves illustrate Logarithmic concentration of primers verses 
crossing point of amplification cycles of each cDNA as it exceeds the background 
fluorescent.  Efficiency appears as the capability of a pair of primers, along with the 
reaction master mix, to amplify a complete pair of DNA fragments.  Efficiency for 
reference gene was examined for each cDNA sample as it gave further evidence of 
cDNA quality (data not shown).  
Negative controls were used as syber green master mix from Roche Applied Science 
with primers and nuclease free water instead of the targeted cDNA.  
Relative quantification was followed using actin as control and normalizing 
material for each pair of primers and each cDNA, (Glyceraldehyde 3-phosphate 
dehydrogenase or GAPDH is preferable, however, for inefficiency it could not be 
used) negatives and calibrator were optional for the Basic Relative Quantification 
analysis, were made in duplicates for 2 rounds of each set of primers and triplicates of 
3 batches.  Seventeen different pairs of primer sequences for seventeen genes 
encoding for the different glycosyltransferases were taken from previous literature 
and synthesized by assistance of the genomics core laboratories facility at KAUST, 
(see Table 2). 
 
 
 
Gene Primer sequence 5'-3' Product 
Size 
E-Value Reference 
C2GlcNAcT-I F:GACGTTGCTGCGAAGG 
R:CCAAGTGTCTGACACTTACA 
131 8.0 × 10−1 
7.0 × 10−3 
Kikuchi, Jiro et al., 2005 
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C2GlcNAcT-II F:GCGAAAGAACCCTCAATCAG 
R: GCTGCAGTTTCCCTTCAGTC 
96 1.5 × 10−2 
1.5 × 10−2 
Bartherl et al., 2008 
C2GlcNAcT-III F: CCCACTGAGCAAAGAAGAGG 
R: GGCATACACAGCTCGCAGTA 
100 1.5 × 10−2 
1.5 × 10−2 
Bartherl et al., 2008 
B1,4GalT-I F: TCACAAGGTGGCCATCATCA 
R: GCAGGACTGGGTGCAAATAATAT 
83 7.0 × 10−3 
2.0 × 10−4 
Sasaki, Norihiko et al., 
2005 
B1,4GalT-III F: CCATGTTGCCGTTGCTATGA 
R: AGTGCTGAGACTCCTCCGAAGT 
76 1.5 × 10−2 
1.0 × 10−3 
Sasaki, Norihiko et al., 
2005 
ST3Gal-I F: TCGGCCTGGTTCGATGA 
R: CGCGTTCTGGGCGGTCA 
63 6.1 × 10−1 
6.1 × 10−1 
Bartherl et al., 2008 
ST3Gal-III F: GGTGGCAGTCGCAGGATTT 
R: CATGCGAACGGTCTCATAGTAGTG 
76 3.9 × 10−2 
1.0 × 10−4 
Higai, Koji et al., 2006 
ST3Gal-IV F: CGGGTGCGAAAGGGTTT 
R:GAGAATCCGAATCTGTTTAGGATTG 
72 6.1 × 10−1 
4.0 × 10−5 
Higai, Koji et al., 2006 
FT1 F: TGAGGGATCACTGCCAAAATG 
R:TCTTGGCAGTTTATGAGCTTTAAAAA 
92 5.0 × 10−3 
1.0 × 10−5 
Higai, Koji et al., 2006 
FT2 F: GCTCGCTACAGCTCCCTCAT 
R: CGTGGGAGGTGTCAATGTTCT 
79 1.5 × 10−2 
5.0 × 10−3 
Higai, Koji et al., 2006 
FT3 F: GCCGACCGCAAGGTGTAC 
R: TGACTTAGGGTTGGACATGATATCC 
75 1.5 × 10−1 
4.0 × 10−5 
Higai, Koji et al., 2006 
FT4 F: AAGCCGTTGAGGCGGTTT 
R:ACAGTTGTGTATGAGATTTGGAAGCT 
88 1.5 × 10−1 
1.0 × 10−5 
Higai, Koji et al., 2006 
FT5 F: TATGGCAGTGGAACCTGTCA 
R: CGTCCACAGCAGGATCAGTA 
100 1.5 × 10−2 
1.5 × 10−2 
Bartherl et al., 2008 
FT6 F: CAAAGCCACATCGCATTGAA 
R: ATCCCCGTTGCAGAACCA 
93 1.5 × 10−2 
1.5 × 10−1 
Higai, Koji et al., 2006 
FT7 F: TCCGCGTGCGACTGTTC 
R: GTGTGGGTAGCGGTCACAGA 
65 6.1 × 10−1 
1.5 × 10−2 
Higai, Koji et al., 2006 
FT8 F: TTGCCATTTATGCTCACCAA 
R: TTCCAGCCACACCAATGATA 
78 1.5 × 10−2 
1.5 × 10−2 
Bartherl et al., 2008 
FT9 F: TCCCATGCAGTTCTGATCCAT 
R: GAAGGGTGGCCTAGCTTGCT 
78 5.0 × 10−3 
1.5 × 10−2 
Higai, Koji et al., 2006 
GAPDH F: CAGCCTCAAGATCATCAGCA 
R: ACAGTCTTCTGGGTGGCAGT 
138 1.5 × 10−2 
1.5 × 10−2 
Higai, Koji et al., 2006 
-Actin F: GCACTCTTCCAGCCTTCC 
R:GCGCTCAGGAGGAGCAA 
   
Table 2. Primers used in real-time PCR analysis of glycosyltransferase expression 
 
Adhesion and Stamper-woodruff Assays: 
For the adhesion assay 1x10
4
 cells were harvested from KG1a, HL60 treated or 
untreated with A3D8.  Cells were washed with 1% BSA, HBSS, 1M HEPES, 1M 
calcium and or 0.8 M EDTA, EDTA treatment was used as a negative controls and 
KG1a cells as positive control. Duplicate were made.  Recombinant E-selectin-Ig was 
resuspended in PBS (5ug/ml), coated on glass slides, and incubated at 4
o
C over night.  
Then, spots of E-selectin were rinsed four times with PBS and blocked with HBSS 
containing 1% of BSA for 1 hour at 37
o 
C.  
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Cells were then perfused on the slides (19) with shear flow created by the action of a 
rotor, and left for 5 minutes, non-adherent cells were washed out by gentle tap of 
slides, and then fixed with paraformaldehyde and examined under the microscope. 
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III. Results 
3.1 Induction of Differentiation 
In order to investigate the CD44-induction of AML differentiation, cells (HL60) were 
treated for 48-72 hours with anti-CD44 mAbs and then were analyzed for morphology 
changes such as, nucleus granularity and change in cells size compared to the 
untreated control cells. 
After 48 hours of of anti-CD44 treatment, we did not observe significant changes in 
cells morphology (data not shown).  However, after 72 hours of treatment, we 
observed a strong decrease in the nucleus to cytoplasmic ratio and multilobular 
nucleus, two signs of morphological differentiation, as shown by Gadhoum and 
Sackstein 2008 (42) (Figure 6). 
 
                 
 
Figure 6: Untreated HL60 cells (left) versus A3D8 treated HL60 cells (right). 
As previously reported differentiation signs appear after 72 hours of A3D8 treatment: 
lower nuclear to cytoplasmic ratio and multilobular nucleus, (42). 
 
Next, we sought to determine the effect of CD44 ligation on HL60 cells proliferation 
capacity and viability as well as markers expression for differentiation (CD15) and 
CLA (marker of CD15s).  
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 The cell count in presence of trypan blue showed a 2-fold decrease in HL60 
proliferation with low to no cell death after 48 hours of treatment (Data not shown).  
In order to assess the changes in markers of differentiation expressed on HL60 cells, 
2x10
5
 cells were stained after 48hours of treatment for the expression of CLA using 
rat anti-human Heca-452 and for the expression of CD15 using FITC conjugated IgM 
CD15 mAb. Samples were performed in triplicate.  Using FACS analysis, we 
observed a higher mean of fluorescent intensity for CLA expression in the untreated 
HL60 compared to the A3D8-treated HL60 (Figures 7 and 8), suggesting that sLe
x
 
sugar caps expression on selectin ligands is decreased after 48 hours of treatment. 
Furthermore, expression of CD15 was significantly higher on treated HL60 cells 
compared to untreated cells.  Taken together, these results showed that CD44-ligation 
induces the differentiation of HL60 cells and are in accordance with previous studies 
(56). 
 
                  
                   
Figure 7: Flow cytometric analysis of HL60 cells stained for differentiation markers 
CD15 and CLA. After CD44-ligation of HL60 cells, we observe an increase in the 
expression of CD15 (Left) and a decrease in CLA expression (Right). 
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(Figure 8); Results from BD FACSDiva software analysis: correlating to the Flow Jo 
results MFI increases for CD15 after treatment, and at the same time CLA decreases 
compared to the untreated cells. 
 
3.2 E-selectin Adhesion Assays 
We next aimed to investigate the capacity of A3D8-treated HL60 cells to adhere to 
E-selectin compared to untreated HL60 cells.  Using E-selectin adhesion assay we 
observed higher adhesion capacity for untreated cells to E-selectin coated slides 
compared to A3D8-treated cells (Figure 9).  KG1a are used here as a positive control 
for E-selectin binding.  To confirm the specificity of E-selectin binding, we proceeded 
to the adhesion assay in the presence of EDTA which inhibited the adhesion 
capability of all the cells as shown in (Figure 9).  Our results suggest that A3D8 
treatment decreases the E-selectin ligand activity of HL60 cells, either by decreasing 
E-selectin ligand expression, hypothesis consistent with the decrease of Heca-452 
signal from FACS analysis (Figure 8), or by decreasing the expression and/or enzyme 
activity of glycosyltransferases responsible for the sugar cap creation on E-selectin 
ligands.  Moreover, these results correlate with preliminary experiment (unpublished) 
of Stamper and Woodruff assay examined by Gadhoum SZ., where both anti-CD44 
treated and untreated AML cells adhered to Chinese Hamster Ovarian cells expressing 
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E-selectins (CHO-E), however, the treated cells were drastically less adhesive to 
CHO-E cells compared to the control (Figure 10). 
 
 
Figure 9: Adhesion Assay: HL60 treated or untreated adhered to E-selectin coated 
slides.  Notice the higher adhesion capacity for KG1a (positive control) and untreated 
HL60 compared to the anti-CD44 treated or EDTA treated cells (negative control). 
 
         
 
 
 
 
Figure 10: Stamper-Woodruff Assay 
showing that anti-CD44 treatment 
significantly inhibited the adherence 
of CHO-E cells to AML 
cells.(Gadhoum S.Z.) 
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3.3 RNA Extraction and Reverse Transcription 
In order to investigate whether the decrease in E-selectin binding is due to a decrease 
in expression of the glycosyltransferases responsible for the sLe
x
 creation, we used 
real time PCR experiments, in which five cell lines were studied, KG1a, 22D, treated, 
untreated HL60 and U937.  After RNA was extracted we sought to determine the 
quality of the extraction by running the samples on agarose gel electrophoresis.  This 
resulted in clear 2 bands of 
28s and 18s mRNA, (figure11), confirming the good quality of the extracted RNA. 
 
               
 
3.4 Primers Effeciency Testing 
We then used RT-PCR to analyze the expression of the enzymes responsible for CLA 
creation on the top of glycoprotein and glycolipids.  We first proceeded to testing the 
primers efficiency, and indeed the primers used were all efficient (Figure 12), except 
for five primers including GAPDH.  Therefore, we decided to use -actin as the 
house-keeping control gene for qPCR normalization.  Inefficient primers were 
reordered for further studies.  Pairs of Primers were efficient with 1.8-2 for each 
product (Figure 12). 
Figure 11: 
Gel electrophoresis for 6 RNA 
samples: KG1a, High CLA clone 
of KG1a, HL60, Treated HL60 
and U937. 
Lane 4 has faint bands and thus 
they've been extracted from other 
3 batches as shown in the three 
final lanes. RT -PCR experiment 
was run for those RNA extracts. 
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C2GlcNAcT-I                                                  C2GlcNAcT-II      
Efficiency: 1.966                                             Efficiency: 1.987 
           
C2GlcNAcT-III                                            B1,4GalT-I 
Efficiency: 2.061                                          Efficiency: 2.057                              
                                                                               
         
     B1,4GalT-III                                                    ST3Gal-IV    
     Efficiency: 2.193                                              Efficiency: 1.927 
           
      FT1                                                                    FT2  
     Efficiency: 1.992                                                Efficiency: 2.004 
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       FT3                                                                FT4 
       Efficiency: 1.986                                           Efficiency: 1.884 
        
     FT6                                                                     FT7 
     Efficiency: 1.880                                                Efficiency: 1.841 
 
       
     FT8                                                                 FT9 
     Efficiency: 1.918                                            Efficiency: 2.007 
       
     -I 
     Efficiency: 1.724                                            Efficiency: 1.830 
 
Figure 12: Efficiency testing of glycosyltransferases:  
All ΔCt for C2GlcNAcTI,II and II, 1,4GalI and II, ST3Gal-1 and IV, FT1, 2, 3, 4, 5, 
6, 7, 8 and 9, as well as for -actin were efficient with statistical significance of 
(p<0.001) as calculated by Light Cycler 480 RT-PCR software. 
 
3.5 Quantitative Polymerase Chain Reaction 
Quantification of glycosyltransferases expression was determined afterwards, using 
triplicates, two batches were used in serial dilution of the primers.  For these 
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experiments, we used the five cDNA derived from the five cell lines previously 
mentioned (Figure 13). 
 
 
ST3-Gal-I                                                                        FT4 
                         
 
 
 
 
FT6                                                                                FT7 
               
 
 
 
 
FT8                                                                                 FT9 
  
 
 
 
 
 
 
 
 
KG1a     HL60    T-HL60    22D       U937 
 
KG1a     HL60    T-HL60    22D       U937 
KG1a     HL60    T-HL60    22D       U937 
 
KG1a     HL60    T-HL60    22D       U937 
 
KG1a     HL60    T-HL60    22D       U937 
 
KG1a     HL60    T-HL60    22D       U937 
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ST3-Gal-II                                                                          C2-GlcNac-TI 
 
 
 
 
 
C2-GlcNac-T-II                                                           C2-GlcNac-T-III 
 
 
 
 
 
1,4T-I                                                                           1,4T-III 
 
  
 
 
 
 
 
 
 
 
 
KG1a     HL60    T-HL60    22D       U937 
 
KG1a     HL60    T-HL60    22D       U937 
 
KG1a     HL60    T-HL60    22D       U937 
 
KG1a     HL60    T-HL60    22D       U937 
 
KG1a     HL60    T-HL60    22D       U937 
 
KG1a     HL60    T-HL60    22D       U937 
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FTI                                                                         FT2 
           
 
 
 
 
FT3 
        
 
 
Figure 13: Relative quantification results from qPCR  for glycosyltransferases 
enzymes expressed in KG1a, HL60, treated HL60, 22D (clone KG1a) and U937 
cDNA.  Red panels show normalized values to -actin expression. 
 
 Interestingly, our data illustrates that different glycosyltransferases were up-regulated 
after treatment of HL60 with anti CD44 mAb compared to the untreated HL60, except 
for FT7 and FT6.  FT7 down-regulation correlates with the decrease in the E-selectin 
binding observed after anti-CD44 treatment.  It has been shown to play a critical role 
in the creation of ESL-1 (an E-selectin ligand) and rolling on selectins.  Clone 22D 
showed upregulated expression for all variants of C2GlcNacT (I, II and III) as well as 
FT2 and 1,4 GalTI and II and lower for the other of enzymes (FT1, FT3, FT4, FT6, 
FT7, FT8, FT9, ST3GalT-I and ST3Gal-II).  Surprisingly, KG1a shows higher 
KG1a     HL60    T-HL60    22D       U937 
 
KG1a     HL60    T-HL60    22D       U937 
 
KG1a     HL60    T-HL60    22D       U937 
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expression for ST3Gal-I, FT1, FT4, FT6, FT8 and FT9 compared to 22D.  We 
observed higher expression of ST3Gal-1, FT1, FT4, FT6 and FT8 on U937 compared 
to KG1a.  The expression of ST3Gal-II, FT3 and FT7 was higher on U937 compared 
to the other cell lines. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
34 
 
IV. Discussion 
With the goal to create a more efficient therapy of AML, we sought to determine if 
the homing capability of AML cells following treatment with anti-CD44 ligation 
inhibits their migration to E-selectin expressing endothelial beds (as exists in bone 
marrow).  This treatment has already been shown to affect the molecular mechanisms 
of a leukemic cell rendering it less harmful, as it can induce differentiation to more 
mature cells, stimulate apoptosis and decrease the proliferation capacity of these 
cancerous cells.  If by using this treatment we can also inhibit their migration to bone 
marrow, we will also decrease the likelihood that the leukemic cells will find a niche 
in the bone marrow and lead to leukemic disease progression.  We aimed in this study 
to determine the adhesion capacity of myeloblastic cells before and after treatment 
with anti-CD44 mAbs.  First we confirmed that the anti-CD44 mAb treatment 
induced differentiation of myeloblasts based on the analysis of cell morphology and 
differentiation marker expression (CD11b and CD15).  Once this was verified, the 
adherence capacity to E-selectin was assessed.  This adhesion was then correlated to 
the expression of key glycosyltransferases known to regulate the expression of the 
sLe
x
 and hence binding to E-selectin.  Our findings strongly correlate to previous 
studies, showing that anti-CD44 mAb treatment of AML cells lead to differentiate and 
subsequently eliminated metastasis/homing (42).  
 
Morphological analysis for differentiation induced through anti-CD44 mAb treatment 
was consistant with previous studies.  We report the presence of granularity in the 
cytoplasm of the AML cells after 48 hours of treatment and after 72 hours a definitive 
decrease of nuclear to cytoplasmic ratio.  Furthermore, flow cytometric analysis 
comparing treated versus untreated cells confirmed differentiation had occurred 
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evident in the increase in CD15 (Le
x
) and CD11b expression correlating with previous 
findings (42).  This differentiation is correlated with a decrease in CLA (sLe
x
).  Thus, 
we conclude that our differentiating treatment was effective and that upon 
differentiation, the Leukemic cells resulted in a decrease in binding the anti-sLe
x
 
mAb, CLA, suggesting that the adhesion of these differentiated cells to E-selectin is 
probably reduced since sLe
x
 expression is necessary for binding.  
 
To directly test this, we next stained the cells before and after induction of 
differentiation with a recombinant E-selectin-hIg and determined binding by flow 
cytometry.  Indeed, as hypothesized, there was a decrease in E-selectin binding upon 
differentiation of AML cells which correlated with the decrease in the sLe
x
 expression 
level.  To further test the E-selectin binding under shear conditions, we examined the 
adhesion capability of AML cells before and after induction of differentiation under 
rotation on immobilized recombinant E-selectin-hIg.  Results from this assay showed 
a decrease in adhesion of treated AML cells to E-selectin-Ig or to CHO-E cells.  This 
decrease can be explained as a result of variety of causes, as it can be a decrease in 
cell surface E-selectin ligands mediating the adhesion either due to  silencing activity 
of HCELL to bind to E-selectin caused by treating AML cells with anti-CD44 
monoclonal antibody (26).  Alternatively, the decrease in adhesion could be due to a 
decrease in expression of glycosyltransferases responsible for the creation of sLe
x
 
such as fucosylransferases (FT7,  FT4, FT9) and sialyltransferases (ST3Gal-III) (22, 
52-54).  Furthermore, an increase in sialidase activity that results in removal of sialic 
acid from the sLe
x
 epitope can lead to lower E-selectin binding to its ligands may also 
be responsible for this decrease in binding observed (42). 
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In conclusion, our results suggest that anti-CD44 treatment may significantly inhibit 
the homing capability of AML cells to the bone marrow niche since  E-selectin is 
constitutively expressed on the bone marrow endothelium making it is an additional 
reason why that anti-CD44 mAb could be a good therapy for Leukemia.  This needs 
to be directly tested in future studies using mouse models of Leukemia. 
 
Data taken from Quantitative Polymerase Chain Reaction (qPCR) experiments show 
that in contrast to the untreated HL60 cells, A3D8-treated HL60 cells up-regulate the 
glycosyltransferases (FT1, FT2, FT3, FT4, FT8, FT9), except for FT7 and even no 
expression for and FT6 (Figure 13), two key glycosyltransferases known to be 
responsible for creating sLe
x
 in blood lineage cells.  However, because the 
glycosyltransferases were minimally increased we can conclude that glycans 
expressions are affected secondary to glycosyltransferases expression within the 
endoplasmic reticulum and/or Golgi Apparatus. Thus, the increased expression of the 
enzymes may not primarily contribute to the low expression of sLe
x
 (CLA) or the 
increase of Le
x
 (CD15) MFI.  Hence, other factors may be possible to their expression 
like sialidase activity (42).  Interestingly, -2,3-sialyltransferase (ST3GalT-I and 
ST3GalT-II) expressed higher on U937 (monocytic lineage) and KG1a 
(promyelocytic lineage) but not on high clone of CLA (22D).  That is further support 
for the presence of secondary contribution of this enzyme to glycans expression and 
thus binding capability of the cells.  We can conclude that these data are of good 
evidence for the existence of other factors that may have a crucial contribution on 
glycans expression that will gradually inhibit homing and metastasis capability of the 
AML cells. 
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 We suggest that a possible factor is sialidase activity that was shown to up-regulate 
CD15 marker on differentiated cells by eliminating the sialic acid on sLe
x
 sugar cap.  
Furthermore, to elucidate the binding capacity of treated AML cells we need to study 
their adhesion capacity to E-selectin under shear conditions using parallel plate flow 
assay.  In parallel plate flow assay, both treated and untreated AML cells (and also 
LSC and HSC later on) will be perfused at defined flow rates (determined using a 
syringe pump) over immobilized recombinant proteins: E, P or L-selectin-hIg 
chimera, or over cells induced (IL-1 and TNF- treated endothelial cells) to express 
these selectins.  We can also identify the specific ligands mediating the interaction 
with a particular selectin, using blot rolling assay in which the PVDF membrane of 
Western blots of whole cell lysate or immuno-precipitation of specific proteins from 
treated and untreated AML cells (and HSC compared to LSCs) will be exposed to the 
flow of selectin expressing cells.  Both Parallel Plate Flow Assay and Blot Rolling 
Assay can be conducted using the flow chamber apparatus outlined in Figure 14. 
 
Fresh samples of leukemic stem cells are needed from leukemic patients for future 
studies and they must be compared to the normal HSCs.  Moreover, in-vivo studies in 
which immune-deficient mice will be transplanted with treated versus untreated 
human AML blasts, are also needed. 
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Figure 14: Schematic illustrating both the Parallel Plate Flow Chamber Assay and 
Blot Rolling Assay.  This setup consists of a microscope connected to a CCD camera 
for real time observation, a syringe pump to create shear stress and perfuse cells and 
Vaccum to create a seal between the chamber and the tissue culture plate of cells or 
the blot (18). 
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V. Conclusion 
 
This study illustrates the importance of CD44-ligation as treatment for myeloid 
leukemic disease and their LSCs lodgment to bone marrow as well as the 
glycosyltransferases role to this function.  It also establish the foundation for further 
experiments.  For example, proteomics study can be used to reveal further selectin 
ligands, characterizing signaling pathway of glycans synthesis can provide a further 
information on the effect of the CD44-ligation on their expression and in-vivo studies, 
in which immune-deficient mice will be transplanted with treated versus untreated 
human AML blasts, are also needed. 
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